Curr Treat Options Oncol 2019 Aug 19
Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.   

Related Questions

Would the presence of peritoneal carcinomatosis change your treatment strategy? If Ki-67 <50%, would you avoid platinum based cytotoxics?